Literature DB >> 9527798

Concentrations of pefloxacin in plasma and tissue after administration as surgical prophylaxis.

B Jacoberger1, G Ubeaud, G Freys, T Pottecher, L Jung, J C Koffel.   

Abstract

Plasma and epiploic-fat drug concentrations determined by high-performance liquid chromatography and fat penetration of pefloxacin and its metabolite (norfloxacin) given for antimicrobial prophylaxis were studied in patients scheduled for colorectal surgery. Concentrations of pefloxacin in plasma decreased about 40% from the beginning of the operation to closure of the peritoneum, and corresponding levels in epiploic fat stayed stable. The plasma and tissue norfloxacin concentrations were very low. Concentrations of pefloxacin in tissue were greater than MIC at which 90% of isolates are inhibited for sensitive bacteria (members of the family Enterobacteriaceae). The penetration of pefloxacin into epiploic fat was about 32%.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9527798      PMCID: PMC105426          DOI: 10.1128/AAC.42.2.425

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  The importance of tissue antibiotic activity in the prevention of operative wound infection.

Authors:  T M Bergamini; H C Polk
Journal:  J Antimicrob Chemother       Date:  1989-03       Impact factor: 5.790

2.  The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection.

Authors:  D C Classen; R S Evans; S L Pestotnik; S D Horn; R L Menlove; J P Burke
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

3.  Penetration of ciprofloxacin into kidney, fat, muscle and skin tissue.

Authors:  F D Daschner; M Westenfelder; A Dalhoff
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

Review 4.  Antimicrobial prophylaxis in surgery.

Authors:  A B Kaiser
Journal:  N Engl J Med       Date:  1986-10-30       Impact factor: 91.245

5.  Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans.

Authors:  J Barre; G Houin; J P Tillement
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

6.  Basic principles in the use of prophylactic antibiotics.

Authors:  H H Stone
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

7.  Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers.

Authors:  A M Frydman; Y Le Roux; M A Lefebvre; F Djebbar; J B Fourtillan; J Gaillot
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

8.  The comparative in-vitro activity of pefloxacin.

Authors:  A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

9.  In-vitro activity of newer quinolones against aerobic bacteria.

Authors:  R Auckenthaler; M Michéa-Hamzehpour; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

  9 in total
  1 in total

Review 1.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.